linjc16/ctgov huggingface dataset:
Explore the Efficiency of Fiberscope-guided Nasogastric Tube Insertion

Study Overview
=================
Brief Summary
-----------------
For Head and neck cancer and uncooperative patients, blind nasogastric tube (NGT) insertion may sometimes be very difficult because of the anatomical obstructions in the pharynx and uncoordinated swallowing motion. To solve the problem, flexible endoscope has been used widely to assist the NGT insertion via direct visual assistance, working channels/guide wires, or suture fixation. Unfortunately, these tools are not easily assessed in the outpatient department. Here, we try to use a simpler method for the flexible endoscope to guide the NGT insertion.

Detailed Description
-----------------
NGT and fiberscope was combined to facilitate NG tube insertion

Official Title
-----------------
Explore the Efficiency of Fiberscope-guided Nasogastric Tube Insertion

Conditions
-----------------
Nasogastric Tube Esophagitis

Intervention / Treatment
-----------------
* Device: Fiberscope-Guided Nasogastric tube insertion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: dysphagia patients who need nasogastric tube feeding Exclusion criteria: Patients who ever had human immunodeficiency virus infection and were not suitable for fiberscope exam without protection sheath

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fiberscope-Guided Nasogastric tube<br>Fiberscope-Guided Nasogastric tube insertion | Device: Fiberscope-Guided Nasogastric tube insertion<br>* Fiberscope-Guided Nasogastric tube insertion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The success rates of fiberscope-guided NG tube insertion | fiberscope-guided NG tube insertion | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer patients, Nutritional status
Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy of the topical therapies Protopic and Advantan as well as their combination against placebo in a Psoriasis Plaque Test

Detailed Description
-----------------
daily psoriasis plaque tests for two weeks and optical coherence tomography (OCT) and 20-MHz-ultrasound on day 0 and day 11, 10 days post end of treatment and 20 days post end of treatment

Official Title
-----------------
Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test

Conditions
-----------------
Psoriasis Vulgaris

Intervention / Treatment
-----------------
* Drug: Protopic, Advantan
* Procedure: Blood and Urine Test
* Procedure: coherence tomography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 Years Negative urine pregnancy test Written informed consent Good compliance Exclusion Criteria: Patients less than 18 years Pregnant patients Patients with renal insufficiency, liver diseases Patients who received systemic antipsoriatic treatment or UV treatment less than 4 weeks prior to study Patients who used topical antipsoriatics within two weeks prior to study Immunosuppressed Patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Protopic, Advantan|nan|
|Procedure: Blood and Urine Test|nan|
|Procedure: coherence tomography|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sum score of psoriasis plaque tests on day 11 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 20-MHz-ultrasound and OCT on day 11 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
topical therapy, Psoriasis Plaque Test
A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Study Overview
=================
Brief Summary
-----------------
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis

Conditions
-----------------
Palmoplantar Pustulosis

Intervention / Treatment
-----------------
* Drug: RIST4721
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least a 6-month history of PPP as defined by the presence of pustules on palms and/or soles, but without evidence of infection on palms and soles Moderate or severe PPP, as defined by Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) ≥8 and Palmoplantar Pustulosis Physician Global Assessment (PPPGA) ≥3 at Day -1, and a minimum of 8 fresh pustules at screening (fresh pustule count on both right/left palms and soles) and 20 fresh pustules at Day -1 (fresh pustule count on both right/left palms and soles) Males and females must be willing to use birth control as indicated Exclusion Criteria: Moderate to severe psoriasis, as defined by plaque psoriasis covering ≥10% of total Body Surface Area (BSA) at Day -1 Subject is known to have an immune deficiency or is immunocompromised Positive test for hepatitis, human immunodeficiency virus (HIV) or tuberculosis Use of topical therapies for PPP within 2 weeks of Day -1 and/or systemic therapies for PPP within 4 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: RIST4721<br>RIST4721 as once-daily 300mg oral solution for 28 days. | Drug: RIST4721<br>* RIST4721 oral solution<br>|
| Placebo Comparator: Placebo<br>Placebo as once-daily 300mg oral solution for 28 days. | Drug: Placebo<br>* Placebo oral solution<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to Baseline | Relative change from baseline in fresh pustule count at Day 28 | Baseline to Day 28 | 
| Log Transformed Ratio of Postbaseline Total Pustule Count at Day 28 to Baseline | Relative change from baseline in total pustule count at Day 28 | Baseline to Day 28 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PPP
BRAVE: Building Resilience and Values Through E-health

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the feasibility and acceptability of tracking survivors' and their caregivers, stressors, affect, and symptoms using an electronic diary method, in the time period surrounding their routine check- up with their oncologist.

Official Title
-----------------
BRAVE: Building Resilience and Values Through E-health

Conditions
-----------------
Survivorship

Intervention / Treatment
-----------------
* Other: Online survey questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 11-25 years old previously received a pediatric cancer diagnosis and treatment for such completed cancer treatment <5 years ago, in remission Own a smart phone or tablet are English proficient Exclusion Criteria: no cognitive, motor, or sensory deficits that could preclude completion of study measures.

Ages Eligible for Study
-----------------
Minimum Age: 11 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Daily Diary Method Cohort<br>Participants will be asked to complete a self-report questionnaire that has been validated to assess daily affect. There are 5 items assessing positive affect (joyful, cheerful, happy, lively, proud) and 5 items assessing negative affect (miserable, mad, afraid, scared sad). The respondent is asked to rate these 10 different feelings on a 5-point Likert scale from 1, not much or not at all to 5, a lot. | Other: Online survey questionnaire<br>* Participants will complete a brief online survey every morning and evening within 1 hour of waking and 1 hour of going to sleep. The surveys will be a combination of measures used to assess affect, stress, and symptoms<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Online survey questionnaire | participants will complete a brief online survey every morning and evening within 1 hour of waking and 1 hour of going to sleep | 21 days |
Incubation Time and Test of Cure of Chlamydia Trachomatis

Study Overview
=================
Brief Summary
-----------------
Objective was to understand the dynamics of Chlamydia trachomatis (Ct) detection by nucleic acid amplification testing (NAAT) after treatment and consequences for test-of-cure practice.

Detailed Description
-----------------
Prospective Cohort Study on Detection of Chlamydial ribosomal ribonucleic acid (rRNA) and deoxyribonucleic acid (DNA) in anorectal and cervicovaginal Chlamydia trachomatis (Ct) infections during 8 weeks after directly observed treatment with Azythromycin. The investigators systematically assessed presence of Ct plasmid DNA and rRNA through multiple time-sequential measurements following treatment with 1000mg Azythromycin. By convenience sampling at our outpatient sexually transmitted diseases (STD) clinic, 46 non-pregnant women and 6 men were included, contributing 45 cervicovaginal and 15 anorectal infections. Over a period of 8 weeks, patients provided a total of 1016 self-taken cervicovaginal and/or anorectal swabs (response: 94%). All patients were negative for Human immunodeficiency virus (HIV), gonorrhea and Lymphogranuloma venereum (LGV), tested in anorectal Ct. Usual care was applied by advising abstinence or safe sex for one week and by providing treatment for steady partners. Participants provided written informed consent.

Official Title
-----------------
Time to Cure Chlamydia Trachomatis: Prospective Cohort Study on Detection of Chlamydial RNA and DNA in Anorectal and Cervicovaginal Infections During 8 Weeks After Directly Observed Treatment With Azithromycin

Conditions
-----------------
Chlamydia Trachomatis Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chlamydia trachomatis diagnosis, age >=18 years Exclusion Criteria: pregnancy, doxycycline treated-Ct, recent treatment with antibiotics, co-infections with other STD

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| chlamydia care as usual<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of detection of Chlamydial rRNA and DNA after treatment | At 1,2,3,4,5,6,7,9,12,16,19,23,26,30,37,44, and 52 days post treatment chlamydial rRNA and DNA is measured. Outcomes are the times to rRNA and/or DNA negative test results. | 0 to 52 days after treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chlamydia trachomatis, anorectal, cervicovaginal, MSM, women, treatment, RNA, bacterial load, sexual behaviour, Azythromycin treated
Transvaginal NOTES Sleeve Gastrectomy

Study Overview
=================
Brief Summary
-----------------
This is a prospective chart review/data collection study of natural orifice translumenal endoscopic surgery (NOTES) for sleeve gastrectomy, that will include questionnaires administered throughout the study. Subjects enrolled will be those intending to have a transvaginal NOTES sleeve gastrectomy. Data will be collected and reviewed through 12 months post-op.

Official Title
-----------------
Natural Orifice Translumenal Endoscopic Surgery (NOTES): Laparoscopic Assisted Trans-Vaginal Sleeve Gastrectomy

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Procedure: Transvaginal NOTES sleeve gastrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: Diagnosis of morbid obesity BMI > 40 Female, age 18-75 Mentally competent to give informed consent Scheduled to undergo a transvaginal NOTES sleeve gastrectomy Exclusion: Pregnant women BMI < 40

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Transvaginal NOTES sleeve gastrectomy<br>Transvaginal NOTES sleeve gastrectomy | Procedure: Transvaginal NOTES sleeve gastrectomy<br>* transvaginal NOTES sleeve gastrectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess outcomes related to the transvaginal NOTES approach to laparoscopic sleeve gastrectomy (through data collection). |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess pain associated with the transvaginal NOTES approach to laparoscopic sleeve gastrectomy (through data collection). |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
obesity, sleeve gastrectomy, transvaginal NOTES
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia

Study Overview
=================
Brief Summary
-----------------
Subjects have acute promyelocytic leukemia (APL) that has come back (relapsed) after initial treatment or has not gone away with initial therapy. This research study involves testing an investigational drug called Tamibarotene in combination with standard treatment for relapsed APL called arsenic trioxide. Tamibarotene has been approved in Japan to treat patients with relapsed APL since April 2005. Tamibarotene is in the same family of drugs as all-trans retinoic acid (ATRA), a medication that subjects received previously in their treatment. ATRA and tamibarotene both cause the APL cells to differentiate (or become) normal non-leukemia cells. Laboratory studies of tamibarotene have shown to be effective in APL. The purpose of this study is to determine if tamibarotene in combination with arsenic trioxide is safe and effective.

Official Title
-----------------
A Phase I Trial of Tamibarotene and Arsenic Trioxide for the Treatment of Relapsed Acute Promyelocytic Leukemia

Conditions
-----------------
Acute Promyelocytic Leukemia

Intervention / Treatment
-----------------
* Drug: Tamibarotene
* Drug: Arsenic trioxide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have diagnosis of relapsed APL Must have completed any prior cancer treatment at least 6 months prior to study Must have had prior treatment that included ATRA

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br>Tamibarotene + Arsenic Trioxide | Drug: Tamibarotene<br>* Self-administered tablets BID (approximately one hour after breakfast & dinner) during each 6 week cycle<br>Drug: Arsenic trioxide<br>* Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the safety and feasibility of combining tamibarotene and arsenic (ATO) for the treatment of patients with relapsed APL. |  | Once the MTD has been reached. |
Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity

Study Overview
=================
Brief Summary
-----------------
The present study on pharmacological intervention in autonomic nervous dysregulation(parasympathetic dysfunction,) regarding insulin resistance, is a concept testing in humans tohelp identify potential new pharmacological target sites in the central nervous system.

Official Title
-----------------
Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity - a Concept Study in Mani

Conditions
-----------------
Insulin Resistance

Intervention / Treatment
-----------------
* Drug: Atropine
* Drug: Physostigmine
* Drug: Placebo Sodium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed written informed consent BMI of lean and abdominally obese men and women weight stable Exclusion Criteria: Ongoing clinically significant diseases History of repeated syncope resting pulse<50 or systolic blood pressure <100

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Atropine|10 ug/kg bolus, 4 ug/kg/h infusion|
|Drug: Physostigmine|0,12ug/kg/min|
|Drug: Placebo Sodium|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study the effect of anticholinergic drugs on insulin sensitivity by assessment of glucose infusion rate during hyperinsulinemic euglycemic clamp. |  | After Insulin bolus, following will be measured; p-glucose (every 5 minutes), blood samples (every 30 minutes), pulse (every 5 minutes the first hour then every 10 minutes), blood pressure will be measured (the same as pulse). | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study the effect of cholinergic stimulation on insulin sensitivity by assessment ofglucose infusion rate during hyperinsulinemic euglycemic clamp. |  | measured; p-glucose (every 5 minutes), blood samples (every 30 minutes), pulse (every 5 minutes the first hour then every 10 minutes), blood pressure will be measured (the same as pulse). | 
| Study the possible difference in effect of cholinergic (physostigmine) andanticholinergic (atropine) drugs on insulin sensitivity in a lean and abdominal obese subgroup of subjects. |  | measured; p-glucose (every 5 minutes), blood samples (every 30 minutes), pulse (every 5 minutes the first hour then every 10 minutes), blood pressure will be measured (the same as pulse). | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Clamp
Hypertension and Sleep Disordered Breathing in Pediatrics

Study Overview
=================
Brief Summary
-----------------
The primary objective is to determine the prevalence of sleep disordered breathing in children with primary hypertension or pre hypertension. The secondary objectives are to determine any association factors for children with primary hypertension or prehypertension to have sleep disordered breathing be it gender, age, body mass index (BMI), family history (hx) or ethnic group.

Detailed Description
-----------------
This is an exploratory, cross sectional study involving identification of the children of the age between 10 years and 17 years diagnosed with primary hypertension who have not been previously diagnosed and or treated for sleep disordered breathing with the revised pediatric sleep questionaire (PSQ) for sleep disordered breathing. The subjects that have shown interest will be mailed the informed consent/assent form to tbe reviewed. The consent/assent form will be handed to the child and all their questions and concerns will be answered in a comprehensible manner.

Official Title
-----------------
Hypertension and Sleep Disordered Breathing in Pediatrics

Conditions
-----------------
Hypertension, Obstructive Sleep Apnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 10 to 17 years old diagnosed with primary hypertension Exclusion Criteria: refused to participate in the study children to secondary hypertension previously diagnosed with sleep disordered breathing

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypertension, obstructive sleep apnea, pediatrics